New PrEP approaches needed
New drugs, technologies and delivery systems for pre-exposure prophylaxis (PrEP) against HIV infection are needed that can provide protection for a wide variety of people with different needs over the course of their sexually active lifespan, according to a paper in The Lancet HIV (doi.org/10.1016/S2352-3018(19)30238-3)
Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate and emtricitabine is highly effective in reducing HIV acquisition, but its efficacy relies on good adherence. According to the authors of the paper this poses a challenge for a number of the most at-risk populations (women, young people, ethnic minority men who have sex with men, and transgender women).
New PrEP agents in clinical development include innovative oral agents such as tenofovir alafenamide and islatravir (MK-8591), long-acting injectables (cabotegravir), broadly neutralising monoclonal antibodies and topical products (including gels, films and enemas). In addition, new drug delivery systems, such as implants and transdermal devices, are promising strategies that are being developed for HIV prevention, the authors say.